Why do animal models (sometimes) fail to mimic human sepsis?

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

2001 • 5,900 citations

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

2003 • 931 citations

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

1987 • 836 citations

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

1993 • 552 citations

Normal Responses to Injury Prevent Systemic Inflammation and Can Be Immunosuppressive

2001 • 514 citations

Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia

2000 • 255 citations

Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation

2001 • 187 citations

Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli

2000 • 172 citations

C4b-binding protein exacerbates the host response to Escherichia coli

1991 • 153 citations

Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells

1989 • 136 citations

Regulation of inflammatory responses by natural anticoagulants

2001 • 135 citations

TNF-α Compensates for the Impaired Host Defense of IL-1 Type I Receptor-Deficient Mice During Pneumococcal Pneumonia

2001 • 125 citations

Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood

2001 • 119 citations

Use of endothelium cultured on microcarriers as a model for the microcirculation.

1982 • 98 citations

Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine.

1995 • 85 citations

Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions

2002 • 71 citations

Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin

1999 • 66 citations

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023].

2002 • 42 citations

Thrombogenic Mechanisms of Antiphospholipid Antibodies

1997 • 38 citations

Summary of Staging Mechanism and Intervention Studies in the Baboon Model of E. coli Sepsis

1990 • 11 citations

Untitled

2002 • 3 citations